Off-the-Shelf cancer treatment trial seeks to tame tough tumors

NCT ID NCT06653023

Recruiting now Disease control Sponsor: Wondercel Biotech (ShenZhen) Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new type of cancer treatment called universal CAR-T cells (REVO-UWD-03) for people with advanced liver cancer or lung cancer. The treatment uses immune cells from healthy donors, engineered to attack cancer, rather than using the patient's own cells. The main goals are to find a safe dose and see if the treatment can shrink tumors in patients who have run out of standard treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710061, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Jiangsu Cancer Hospital
RECRUITING

Nanjing, China

Contact

Contact

Conditions

Explore the condition pages connected to this study.

HCC - HEPATOCELLULAR CARCINOMA NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)